Top hashtag#ADC Events in 2024 Catailyst, Life Science Data , Alerts & Visuals "ai engine" analyzed 70,000+ press releases since January 2024, pinpointing 185 significant events TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer catailyst.ai/news/GLN-56355

Trending Topics Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age #ArtificialInteligence #MachineLearning #NLP #LLM catailyst.ai/home

Trending Topics @FireflyNeuroscience Announces Closing of #Merger Agreement and is Scheduled to Begin Trading on #Nasdaq Under the Ticker Symbol $AIFF #ArtificialInteligence #MachineLearning #NLP #LLM catailyst.ai/home

Trending Topics AscendisPharma #FDA Approves #YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for #Hypoparathyroidism in Adults catailyst.ai/news/GLN-60803

Midweek Read, August 21: Catailyst Biopharma Update - mailchi.mp/catailyst.ai/w…

Trending Topics catailyst.ai/home Incyte Data $INCY Versant Ventures /Novartis launch Borealis Bayer | Pharmaceuticals Initiate Phase2 for CKD Tris Pharma initiates Pivotal Phase3 for Pain

Weekend Read, August 23: Catailyst Biopharma Update - mailchi.mp/catailyst.ai/w…

Midweek Read, August 28: Catailyst Biopharma Update - mailchi.mp/catailyst.ai/w…

Long Weekend Read, August 28: Catailyst Biopharma Update - mailchi.mp/catailyst.ai/w…

Midweek Read, Sept 4: Catailyst Biopharma Update - mailchi.mp/catailyst.ai/w…

@ModalisTherapeutics FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD) catailyst.ai/news/BWN-74784

Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology Series A, $15.3M catailyst.ai/news/BWN-74812

$MESO Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch #PDUFA January 7, 2025 catailyst.ai/news/GLN-62794

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 catailyst.ai/news/BWN-74772

IRLAB has Enrolled the Last Patient in the Phase IIb Study of Pirepemat catailyst.ai/news/AWN-11914 #Parkinson's disease

Catailyst Product Demo Series: Oct 9, 11 AM Eastern Time (US and Canada) lnkd.in/e9upr3uH Revolutionizing life science data access with its proprietary AI. Discover how Catailyst's powerful platform is transforming the day-to-day work for life science data access.

Catailyst, Life Science Data , Alerts & Visuals, Inc. #TrendingNow #Topics FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy for Patients with Grade 2 IDH-Mutant Glioma catailyst.ai/news/BWN-75569

What a journey for Intracellular Therapies Inc ($ITCI) - acquired yesterday at the ripe age of 23 yrs old. Series A of $2.9M in 2002. Moshe Alafi, called one of the founders of biotech (whose VC firm backed Cetus, Amgen, ABI, others) was the lead of the A-round. Over next

Atara Biotherapeutics received a Complete Response Letter (#CRL) from US #FDA regarding the #BLA for EBVALLO™ (tabelecleucel) to treat post-transplant lymphoproliferative disease (PTLD) $ATRA catailyst.ai/pressRelease/4…

Clinical Program Update @Novotech Novotech Releases Report on Current State of Triple-Negative Breast Cancer Clinical Trials catailyst.ai/pressRelease/4…